Pharmacodynamics. Omega-3 polyunsaturated fatty acids - eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - are essential fatty acids. the preparation actively affects blood plasma lipids, reducing the level of tg, LDL and LDL. the preparation affects hemostasis and reduces the risk of thrombus formation by affecting the aggregation ability of platelets; moderately lowers hell. The normalization of the blood lipid spectrum also occurs due to a decrease in the synthesis of tg in the liver, since EPA and DHA inhibit the esterification of other fatty acids, as well as by reducing the amount of free fatty acids (the number of peroxisomes of β-oxidation of fatty acids increases) participating in the synthesis of tg. a decrease in the synthesis of tg leads to a decrease in the level of LPONP.
α-Tocopherol is an antioxidant that prevents the oxidation of polyunsaturated fatty acids.
Pharmacokinetics. Pharmacokinetic data are not available.
For the primary prevention of atherosclerosis and cardiovascular diseases; as part of the complex therapy of atherosclerosis, ischemic heart disease, ag; in the secondary prevention of myocardial infarction in addition to standard treatments (for example statins, antiplatelet preparations, β-adrenergic receptor blockers, APF inhibitors); with hypertriglyceridemia, in addition to diet therapy, if the latter is not effective enough.
The preparation is taken with meals.
For the purpose of prevention, adults and children over the age of 12 are prescribed 1 capsule per day. According to individual indications, the dose of the preparation can be increased to 2 capsules per day.
In the complex therapy of cardiovascular diseases - 2 capsules per day.
For hypertriglyceridemia, the initial dose is 2 capsules per day (in 1 or 2 doses). In case of insufficient effect, the dose of the preparation is increased to 4 capsules per day. Treatment must be continued until the desired therapeutic effect is achieved.
Hypersensitivity to any of the components of the preparation. exacerbation of chronic cholecystitis and chronic pancreatitis, exacerbation of diseases of the hepatobiliary system, cholelithiasis, pathological conditions accompanied by hemorrhagic syndrome.
From the immune system: hypersensitivity reactions.
From the side of metabolism and nutrition: hyperglycemia.
From the nervous system: dizziness, dysgeusia, headache.
Vascular disorders: arterial hypotension.
On the part of the blood and lymphatic system: hemorrhagic diathesis.
From the respiratory system, chest and mediastinal organs: dryness of the nasal mucosa.
From the gastrointestinal tract: dyspeptic disorders, nausea, abdominal pain, gastrointestinal disorders (gastroesophageal reflux, belching, vomiting, flatulence, diarrhea, constipation), gastritis, gastroenteritis, bleeding from the lower digestive tract.
From the hepatobiliary system: impaired liver function.
Skin and subcutaneous tissue disorders: skin rash, itching, skin redness, urticaria, acne.
Laboratory indicators: an increase in the number of leukocytes, the level of LDH in the blood, an increase in the activity of transaminases.
In the case of a moderate increase in bleeding time (when using the preparation in high doses, that is, 4 capsules per day), it is necessary to monitor the condition of patients receiving anticoagulant therapy, and, if necessary, adjust the dose of the anticoagulant accordingly. it is necessary to take into account the possibility of an increase in bleeding time in patients with an increased risk of developing hemorrhages (due to severe trauma, surgery, or other reasons).
The preparation should not be prescribed for the treatment of exogenous hypertriglyceridemia (type I hyperchylomicronemia).
In patients with hepatic impairment (especially when taking the preparation in high doses), regular monitoring of liver function (ALT and ASAT) is necessary.
The likelihood of side effects is reduced when the preparation is taken with meals.
Use during pregnancy and lactation. The use of the preparation during pregnancy is possible only as directed by a doctor, taking into account the risk / benefit ratio. During breastfeeding, the preparation can be used after consulting a doctor.
The ability to influence the reaction rate when driving or working with other mechanisms. Does not affect.
Children. Due to the lack of data on efficacy and safety, the preparation is not used in children under 12 years of age.
It is not recommended to prescribe in combination with fibrates due to lack of clinical experience. the appointment of epadol-neo simultaneously with warfarin does not lead to hemorrhagic complications, however, in the case of combined use of these preparations or termination of treatment with epadol-neo, prothrombin time should be monitored.
In case of an overdose, allergic reactions may be noted, similar to those that are detected with side effects. treatment: symptomatic therapy.
In its original packaging at a temperature not exceeding 25 ° C.
There are no reviews for this product.